Joint Commission Standards for Pain Assessment and Treatment

The Joint Commission Standards for Pain Assessment and Treatment were approved in 1999, making pain assessment and treatment mandatory for accredited health-care organizations. They emerged from a push to address pain that had long gone untreated, but also from a changing medical system in which pain scores, patient satisfaction, pharmaceutical promotion, and opioid prescribing increasingly overlapped. The book presents the standards as consequential not because they supplied a settled measure of pain, but because they helped make pain a formal institutional priority before clinicians had resolved how to assess it or what consequences broader treatment might bring.

Origins in a Changing Medical System

When OxyContin was introduced in 1996, doctors, hospitals, and accreditation boards were taking up Pain as the fifth vital sign: pain was to receive attention alongside blood pressure, heart rate, respiratory rate, and temperature. The shift coincided with the growing treatment of patients as health-care consumers. Formal surveys, including those conducted by Press Ganey, allowed patients to rate their care, while hospitals and doctors competed for high scores. The book describes the resulting incentive for clinicians to treat pain liberally, or risk losing reimbursements.

In 1999, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) advanced that movement by approving mandatory standards for pain assessment and treatment. The measure gave the priority institutional force: pain was no longer only a clinical concern or an appeal to individual judgment, but a required subject of assessment and care. The account establishes the standards’ mandate, while also showing that the meaning of adequate relief remained unsettled.

A Standard Becomes a Marketing Opportunity

Purdue Pharma quickly recognized the commercial value of the new requirements. In its 2000 budget planning, the company described an opportunity to position itself as a leader in helping hospitals meet JCAHO requirements, including through pain-assessment and pain-management materials. This made compliance with a health-care standard a potential route for the manufacturer to become more present in hospital practice.

The planned materials were substantial and branded: $300,000 in OxyContin scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards promoting pain as the fifth vital sign. The company also envisioned health-care workers carrying Purdue-branded lanyards. The standards did not themselves endorse OxyContin, but Purdue sought to associate its product and its materials with the institutional effort to improve pain care.

That effort unfolded amid confident claims about opioid safety. Purdue representative Dr. J. David Haddox promoted OxyContin for chronic pain beyond cancer and cited addiction rates below 1 percent; a 1996 company training session characterized doctor-caused addiction as exceptionally rare. Sales representatives carried the message to doctors and dentists nationwide, presenting prescribing the drug for a wide range of pain as responsible care. The standards’ demand for attention to pain thus entered a clinical environment in which a manufacturer was actively defining both the problem and a medication-based response.

Measurement and Its Unresolved Limits

The drive to assess pain promised consistency, but the book emphasizes that the measure itself was far from objective. Pain is not visible, and asking patients to rate it could make care easier to standardize without establishing a common scale of experience. A person in transition labor and someone with a stubbed toe could each report a score of ten, depending on their tolerance. Experts later acknowledged that the apparent precision of such scales did not mean they captured comparable suffering.

A 2000 New York Times article reflected the widespread concern that pain had been undertreated. It described an older woman in a nursing home with severe osteoporosis and pulmonary disease who had received only Tylenol, amid the mistaken belief among some health-care workers that adequate pain relief could cause addiction. The standards responded to a real problem, but the book notes that the question of what constituted adequate relief remained unanswered. The ease of assigning a number did not resolve how much treatment a patient needed.

The account further distinguishes the administrative usefulness of pain scores from their clinical effects. Quantifying pain could standardize procedures, yet reliance on pain scales was not shown to correlate with improved patient outcomes; the book says it also had the effect of increasing opioid prescribing and opioid abuse. The standards made assessment compulsory, but assessment alone could not guarantee that treatment decisions were well calibrated.

Clinical Consequences and the Standards’ Significance

The pressure to make pain a priority reached emergency medicine as well as accreditation policy. Carilion Clinic emergency-medicine head John Burton recalled that physicians had been urged to take pain more seriously. He later recognized that his own belief that a two-week supply of opioid pills could not lead to addiction had been wrong. His recollection gives the change a clinical dimension: the new emphasis did not arrive with a complete understanding of the risks attached to prescribing.

The standards therefore sit within a tension rather than a simple policy success or failure. They gave institutional force to the effort to correct undertreatment, including the neglect of patients whose suffering had been minimized. At the same time, the appeal of measurable scores, reimbursement incentives, and Purdue Pharma’s branded materials could align improved pain attention with expanded opioid use. The book’s account does not make the standards the sole cause of increased prescribing; it shows how a mandatory system of assessment could be taken up within a commercial and clinical environment that had not settled the limits of measurement, the meaning of adequate relief, or the risks of the treatment being promoted.